Cannabinoid Biosynthesis Poised as Potential Game-Changer

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
1,392
Cannabinoid Biosynthesis Poised as Potential Game-Changer in Drug Development

NetworkNewsWire Editorial Coverage: As the marijuana market continues its widespread growth, researchers remain merely at the threshold of exploring the manifold potential medical applications of cannabis. At present, more than 90 individual cannabinoid compounds have been discovered within the cannabis plant—each one potentially possessing crucial disease-fighting properties either on its own or combined with other compounds. Historically, however, it has been incredibly difficult to extract most of these compounds from the marijuana plant in adequate quantities and purities to be tested pharmaceutically. Overcoming this stumbling block in medical cannabis advancement, Vancouver-based biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile) has developed a pioneering, high-yield biosynthesis process that enables the manufacture of all 90+ naturally occurring cannabinoids. This groundbreaking development could have an enormous impact in forwarding the efforts of other companies within the cannabis sector, including GW Pharmaceuticals (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Axim Biotechnologies, Inc. (OTCQB: AXIM) and 22nd Century Group, Inc. (NYSE: XXII).

InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) novel approach to cannabinoid biosynthesis represents a potentially game-changing breakthrough in drug development. Many efforts by other companies to develop synthetic cannabis derivatives have failed. In comparison with other microbial platforms, InMed’s E. coli system has proven, through substantial experimentation, to be heartier and more efficient for the manufacturing of cannabinoids.

The process of naturally sourcing most cannabinoid compounds from the cannabis plant is extremely time-consuming, involving the tasks of planting, growing, harvesting and extracting. It is also very costly; can be low-yielding because of crop fluctuations; and involves various hard-to-remove impurities like pesticides, herbicides and fertilizers. Additionally, this process yields only two to three cannabinoids that can reach adequate quantities to justify the process; the remaining cannabinoid compounds are only yielded in trace amounts and are not accessible through natural sources.

While many have tried to chemically synthesize these compounds for pharmaceutical use, the chief problem with such an approach is it is usually very hard to derive cannabis compounds that are identical to the ones that occur naturally. Slight variations in structure can change both the effectiveness and safety of these compounds. The difficulty, tedium, costliness and time-consuming nature of the process is, overall, off-putting and creates a great deal of chemical waste.

The proprietary cannabinoid manufacturing process pioneered by InMed addresses this problem through biosynthesis, which is the process of utilizing naturally occurring cannabinoid DNA to produce cannabinoid compounds in a laboratory setting. The advantages of this process are multifold, resulting in:

Compounds that are identical to naturally occurring cannabinoids
Pure, individual cannabinoids that can be manufactured without the necessity of separating the many compounds from one another
A time- and cost-effective process
High quality control throughout the process thanks to production in a laboratory setting
The capability for all 90+ cannabinoids to be manufactured for the same reasonable cost
InMed is thus able to tap into the enormous medical potential of every cannabinoid, in particular the minor ones, due to this ability to access them in an economically sound way. The financial and time-consuming nature of other biosynthesis methods continue to pose stumbling blocks for other pharmaceutical companies.

Recently, InMed announced the filing of a provisional patent application—the first of many—relating to this proprietary biosynthesis program for manufacturing cannabinoids (http://nnw.fm/Z30dH). Once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions on a global scale, this first patent application will give InMed significant commercial protection for its biosynthesis program, which is an E. coli-based expression system. This series of patent applications will particularly focus on the superiority of E. coli-based expression systems in comparison to other approaches; maximizing production of cannabinoids and related compounds through gene optimization; and additional proprietary developments and data related to InMed’s breakthrough biosynthesis program. Over time, InMed intends to actively convert this first patent filing, along with subsequent provisional patents, into national-stage filings in every major commercial jurisdiction.

InMed’s revolutionary cannabinoid biosynthesis program is one of three core assets for the company. The other two are a bioinformatics assessment tool that targets specific cannabinoids in treating key diseases and a drug development program that includes INM-750 for Epidermolysis bullosa and INM-085 for glaucoma.

InMed is assembling a strong management team to bring its biosynthesis program to commercialization. This team includes Ben Paterson, P.E., whose consulting services were recently retained by InMed (http://nnw.fm/vx1Bo). Paterson previously served as a senior engineering advisor for Eli Lilly and Company, spending 24 years in that company’s biosynthesis division. His extensive expertise will help InMed transition from pilot-scale to commercial-scale manufacturing.

The company’s management team also includes president and CEO Eric A. Adams, who is a veteran biopharmaceutical executive with extensive experience in company and capital formation, global market development, mergers and acquisitions, and licensing and corporate governance; Chief Scientific Officer Dr. Sazzad Hossain, Ph.D., M.Sc., who has more than two decades of academic and industrial experience in new drug discovery and natural health product development; Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM, who is a proven leader in developing cannabinoid therapies; Alexandra D.J. Mancini, M.Sc., who serves as the senior vice president of clinical and regulatory affairs and possesses more than 30 years of global biopharmaceutical R&D experience, with emphasis in clinical development and regulatory affairs; and CFO Jeff Charpentier, who is a biopharmaceutical industry veteran with more than 25 years of experience.

InMed’s breakthrough approach to cannabinoid biosynthesis has enormous potential in helping other companies in their cannabis-related drug development efforts—companies like GW Pharmaceuticals (GWPH), the company behind the world’s first prescription drug derived from the cannabis plant, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis. GWPH’s lead cannabinoid product candidate is Epidiolex®, a liquid formulation of pure plant-derived cannabidiol being developed for the treatment of a number of rare childhood-onset epilepsy disorders. Other companies include Zynerba Pharmaceuticals (ZYNE), whose product candidates are “synthetically manufactured per FDA/CGMP regulations” in an effort to “provide consistent potency and eliminate impurities in the product”; Axim Biotechnologies (AXIM), which is developing a clinical pipeline of cannabinoid-based products such as its MedChewRx™ chewing gum for the treatment of irritable bowel syndrome; and 22nd Century Group (XXII), a plant biotechnology company focused on genetic engineering and plant breeding which allows the increase or decrease of the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants. The availability of all 90+ cannabinoid compounds enabled by InMed’s process could mean the difference between success and failure in the development of drugs to treat various key diseases.

“This novel approach to the biosynthesis of cannabinoids is a game-changer for drug development,” said Dr. Vikramaditya Yadav, assistant professor of Chemical and Biological Engineering at the University of British Columbia and a co-inventor of InMed’s biosynthesis technology (http://nnw.fm/Z30dH). “The importance of producing cannabinoids that are identical to the naturally occurring compounds cannot be overstated. Many drug development efforts with synthetic derivatives have failed.”

With roadways opening up in cannabinoid research and this pioneering new access to every cannabinoid compound rather than just a few of them, the potential is virtually limitless as companies like those named pursue drug development activities within the medical cannabis field. There is no telling what breakthrough cures and treatments may emerge as a result, but it is indeed an exciting time in the burgeoning cannabis space.

For more information on InMed Pharmaceuticals, please visit: InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

InMed Pharmaceuticals, Inc. (INM) Stock Research Links

INM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 362

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 39

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 481

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 419

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 583

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 407

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Daily Insights on WisdomTree Fund Prices and Holdings Update

Updated Category News Views 284

WisdomTree Fund Prices Overview In today’s ever-evolving financial landscape, understanding fund prices is crucial for investors. WisdomTree Issuer plc offers a range of funds that are pivotal to the investment strategy of many. With the latest updates from the fund market, let's delve into the details of some notable WisdomTree funds available for investment. Key...

Continue Reading
Impact of Drug Tariffs on American Patients and Insurers

Updated Category News Views 290

Understanding the Proposed Drug Tariffs Introduced by the Administration Recent discussions have centered around proposed 100% tariffs on foreign pharmaceuticals, primarily advocated by the administration. Economists warn that these tariffs will place a heavy financial burden on American patients and insurers rather than the foreign drug manufacturers. Economic Insights...

Continue Reading
AvidXchange Q2 2025 Results: Growth Amid Strategic Changes

Updated Category News Views 445

AvidXchange Reports Strong Financial Growth in Q2 2025 AvidXchange Holdings, Inc. (Nasdaq: AVDX), a leader in accounts payable (AP) automation software, has published its financial results for the second quarter ended June 30, 2025. The company showcases growth despite various strategic changes, particularly surrounding its pending acquisition. Financial Highlights for Q2...

Continue Reading
Talkiatry Ranks #6 in Digital Health Innovation for 2024

Updated Category News Views 552

Talkiatry Achieves Recognition in Digital Health Talkiatry has been honored as the sixth most innovative digital health startup for 2024. This accolade is a testament to the significant impact the organization is making in the field of behavioral health care. Significance of the CB Insights Ranking Chosen by CB Insights, Talkiatry's ranking reflects a combination of...

Continue Reading
Innovative Partnership Enhances SBA Loan Accessibility for Businesses

Updated Category News Views 267

BizBuySell and LoanBud Collaboration Enhances Financing for Businesses BizBuySell, the leading business-for-sale marketplace, has teamed up with LoanBud, a fintech innovator specializing in SBA financing. This collaboration significantly transforms the experience of buying or selling small businesses by increasing transparency and clarity in the financing process from the...

Continue Reading